Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 16,987

Document Document Title
WO/2013/045380A2
The present invention relates to mGluR5 positive allosteric modulators (PAM) and methods for identifying pharmaceutically acceptable compounds with high tolerability and safety, which method comprises the use of at least one non-competit...  
WO/2013/045885A1
The invention provides a method of treating mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) in a patient, comprising administering to the patient autologous erythrocytes that contain thymidine phosphorylase and are free of ...  
WO/2013/045380A3
The present invention relates to mGluR5 positive allosteric modulators (PAM) and methods for identifying pharmaceutically acceptable compounds with high tolerability and safety, which method comprises the use of at least one non-competit...  
WO/2013/049289A1
Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes, and for reducing weight gain. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.  
WO/2013/046335A1
[Problem] In a non-aqueous patch containing lidocaine, the adhesive force of the preparation tends to lower with an increase in the content of lidocaine. To release an effective amount of lidocaine from a patch to the skin, it is a commo...  
WO/2013/043580A2
The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide contain...  
WO/2013/043580A3
The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide contain...  
WO/2013/039197A1
An adenosine analog noraristeromycin (NAM) represented by this formula and having a selective inhibitory activity against IκB kinase α is used as: a therapeutic agent against recurring castration-resistant prostate cancer; a contracept...  
WO/2013/039244A1
Provided is an agent for stimulating skeletal muscle regeneration in muscle disease or myopathy. The agent for stimulating skeletal muscle regeneration contains chondroitinase as the active ingredient and accelerates regeneration of musc...  
WO/2013/038740A1
The present invention provides: a method for treating muscular atrophy; and a method and a means both for promoting muscle hypertrophy. Specifically, the present invention provides a method for screening for a substance or factor capable...  
WO/2013/040417A1
Amphiphilic cationic polymers comprising a biocompatible amphiphile linked to an organic cation are provided. The polymers complex with therapeutic agents and facilitate delivery of such therapeutic agents, particularly therapeutic nucle...  
WO/2013/035047A1
The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provid...  
WO/2013/035712A1
The purpose of the present invention is to provide a novel medicinal agent and a novel method both of which can be used for treating ALS (amyotrophic lateral sclerosis), preventing the progression of the phase of ALS, treating a symptom ...  
WO/2013/036875A1
The present invention relates to methods of producing chondrocytes, improving the phenotype of a chondrocyte population, promoting chondrogenesis, maintaining a cell population in a differentiated state or increasing the number of cells ...  
WO/2013/030569A2
The present invention discloses cell penetrating peptides and conjugates of a cell penetrating peptide and a cargo molecule.  
WO/2013/030569A3
The present invention discloses cell penetrating peptides (CPP or membrane translocating peptide) and their conjugates with cargo molecules. The peptides are useful as drug delivery systems, particularly as delivery vehicles for nucleoti...  
WO/2013/029431A1
Disclosed are tosylate salts of benzodiazepine derivatives, their polymorphic forms, preparation methods and uses thereof, in particular to a tosylate salt of 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1 ,4]benzodiazepine...  
WO/2013/031749A1
The present invention addresses the problem of providing a physical activity promoter that includes lactic acid bacteria from the human gut and/or a treated product of such lactic acid bacteria, or a food product composition for promotin...  
WO/2013/026099A1
The present disclosure provides proteins comprising antibody antigen binding domains that bind to Fn14 and uses thereof. The present disclosure also provides methods for treating wasting disorders, such as cachexia.  
WO/2013/024311A1
The invention refers to the use of an amidoxime derivative of formula (I) or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition for the prevention and/or treatment of muscle atrophy.  
WO/2013/024898A1
The primary purpose of the present invention is to provide a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. Examples of the present invention can include a heterocyclic compound represented by general formul...  
WO/2013/021891A1
The purpose of the present invention is to provide an amino-acid-containing composition for recovering from muscle fatigue. An amino-acid-containing composition for enhancing the recovery from muscle fatigue, which comprises the amino ac...  
WO/2013/022052A1
Provided is a medicinal agent for medical applications, which can act on the function of a target cell specifically. The medicinal agent for medical applications comprises: a cell-incorporated substance that can be incorporated into a ta...  
WO/2013/023104A1
A method of manufacturing an anhydrous copper complex of formula C12H10CICuN2O4 and methods of treating neuromuscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthr...  
WO/2013/018695A1
To provide a heterocyclic compound which has an RORγt inhibitory effect. A compound represented by formula (I) or a salt thereof. (In the formula, ring A represents an optionally substituted cyclic group; Q represents a bonding hand or ...  
WO/2013/017672A1
The invention discloses a mammal sestrin product applicable in muscle atrophy, as well as any recombinant construction (vectors) comprising this mammal sestrin. A non-human animal model of muscle cell hypertrophy is also disclosed. In pa...  
WO/2013/014565A1
The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. These salts may be formulated as pharmaceutical compositions....  
WO/2013/007003A1
Disclosed is the use of acetylacetic acid in preparing drugs for promoting the proliferation of skeletal-muscle cells, the skeletal-muscle cells being myoblasts, wherein the acetylacetic acid promotes the proliferation of the skeletal-mu...  
WO/2013/007663A1
The invention relates to compounds that act as selective glycogen synthase kinase 3 (GSK-3) ligands and can be used for the treatment of GSK-3-mediated diseases. The compounds of the invention act as glycogen synthase kinase 3 (GSK-3) in...  
WO/2013/002248A1
The purpose of the present invention is to provide: a novel compound which has an S1P lyase inhibitory activity and can induce the reduction in the number of lymphocytes, or a pharmaceutically acceptable salt thereof; and a pharmaceutica...  
WO/2013/003593A1
The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70. In a preferred embodiment, the composition comprises...  
WO/2013/003641A2
This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one...  
WO/2012/177653A2
Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular junction. Compositions include a neuromuscula...  
WO/2012/175379A1
The invention relates to a homeopathic composition for effectively treating and preventing back, sciatic, or lumbar pain. The composition includes Cuprum metallicum, Staphysagria, Ribes nigrum, and preferably includes Spigelia.  
WO/2012/172012A1
New treatment for muscular dystrophies The invention provides a miRNA-21 inhibitor and pharmaceutical compositions comprising said miRNA-21 inhibitor together with pharmaceutical excipients and carriers for use in the treatment of a musc...  
WO/2012/171065A1
The present invention relates to pharmaceutical compositions comprising DITPA, and methods and uses of the pharmaceutical compositions for the treatment for Allan-Herndon-Dudley syndrome including a dosage regime.  
WO/2012/173581A4
The present invention relates to the unit dosage forms comprising a. thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as a muscle relaxant, b. etodolac or a ...  
WO/2012/173581A1
The present invention relates to the unit dosage forms comprising a. thiocolchicoside or a pharmaceutically acceptable salt thereof or any therapeutically active optically pure stereoisomer thereof as a muscle relaxant, b. etodolac or a ...  
WO/2012/174537A3
The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided is a...  
WO/2012/173184A1
[Problem] To provide a LELIA (Liposome-based Enzyme-Linked ImmunoAssay) method using recombinant proteoliposomes, wherein the baseline is sufficiently lowered, allowing the measurement of trace substances that were previously difficult t...  
WO/2012/162778A1
In general, the present invention relates to oral pharmaceutical compositions comprising at least one muscle relaxant and at least one non-steroidal anti-inflammatory drug, in combination with pharmaceutically acceptable excipients, said...  
WO/2012/164234A1
The present invention provides an inhibitor of intracellular protein degradation for use in the treatment and prevention of muscular dystrophy in a mammal. In particular, the invention provides an autophagy inhibitor and/or an inhibitor ...  
WO/2012/161301A1
A P2X4 receptor antagonist such as paroxetine and a diazepinedione derivative represented by general formula (IX) is used as a prophylactic or therapeutic agent for neuropathic pain associated with Guillain-Barre syndrome. (In the formul...  
WO/2012/157746A1
The present invention provides a screening method for a preventive or therapeutic agent for an autoimmune disease, comprising evaluating agonist activity or antagonist activity of a test compound on a lysophosphatidylserine receptor usin...  
WO/2012/156351A1
The present application relates to the field of motor neuron diseases, most particularly to amyotrophic lateral sclerosis and spinomuscular atrophy. Provided herein are strategies to improve symptoms and increase survival in patients wit...  
WO/2012/153191A1
The present invention provides methods of increasing muscle mass and muscle miochodrial oxidative metabolism. Additionally, the invention provides treating various disorders associated with mitochondrial dysfunction, including but not li...  
WO/2012/153635A1
The present invention addresses the problem of providing a technique for introducing a PMO of markedly improved cell permeability and of considerably improved introduction efficiency. The present invention thereby addresses the problem o...  
WO/2012/150960A1
Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA s...  
WO/2012/147597A1
The present invention addresses the problem of treating camptocormia related to the external abdominal oblique muscle. This problem can be solved by administering a local anesthetic to the external abdominal oblique muscle.  
WO/2012/147470A1
[Problem] To provide a therapeutic agent which can promote the recruitment of PDGFRα-positive cells such as bone marrow-derived mesenchymal stem cells in blood and the accumulation of the PDGFRα-positive cells in damaged tissues, both ...  

Matches 201 - 250 out of 16,987